{"id":"NCT02177032","sponsor":"Novartis","briefTitle":"Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age","officialTitle":"Phase 3, Randomized, Stratified, Open Label, Multicenter, Controlled Clinical Study to Evaluate Safety and Immunogenicity of a Rabies Vaccine Administered, With and Without Human Rabies Immunoglobulin, Using the New \"4-sites, 1-week\" Intradermal Regimen for Postexposure Prophylaxis Compared to the Currently Recommended \"2-sites, TRC\" Intradermal Regimen in Children and Adults Subjects.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06","primaryCompletion":"2014-10","completion":"2015-08","firstPosted":"2014-06-27","resultsPosted":"2017-04-07","lastUpdate":"2017-04-07"},"enrollment":885,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Rabies Infection"],"interventions":[{"type":"BIOLOGICAL","name":"Rabies vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Rabies vaccines + Rabies immunoglobulins","otherNames":[]},{"type":"BIOLOGICAL","name":"Rabies vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Rabies vaccines + Rabies immunoglobulins","otherNames":[]}],"arms":[{"label":"4-sites, 1-week without HRIG","type":"EXPERIMENTAL"},{"label":"4-sites, 1-week with HRIG","type":"EXPERIMENTAL"},{"label":"2-sites, TRC without HRIG","type":"ACTIVE_COMPARATOR"},{"label":"2-sites, TRC with HRIG","type":"ACTIVE_COMPARATOR"}],"summary":"Demonstrate non-inferiority of the immune response between new versus the currently recommended intradermal regimens of rabies vaccine when administered with or without rabies immunoglobulins in healthy subjects ≥ 1 years of age.","primaryOutcome":{"measure":"Percentages of Subjects With RVNA Titer >= 0.5 and Vaccine Group Differences (\"4-sites, 1-week\" to That of \"2-sites, TRC\" ID PEP Regimen of the PCEC Rabies Vaccine With or Without HRIG Administration)","timeFrame":"Study day 50 (D50)","effectByArm":[{"arm":"TOTAL 4-sites, 1-week","deltaMin":99,"sd":null},{"arm":"TOTAL 2-sites, TRC","deltaMin":100,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["Philippines","Thailand"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":356},"commonTop":["INJECTION SITE ERYTHEMA","INJECTION SITE PAIN","VACCINATION SITE ERYTHEMA","HEADACHE","FATIGUE"]}}